Paul D Kassner
Overview
Explore the profile of Paul D Kassner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bissonnette R, DuBois J, Facheris P, Del Duca E, Kim M, Da Rosa J, et al.
Allergy
. 2023 Nov;
79(4):924-936.
PMID: 37984453
Background: RPT193 is an orally administered small molecule antagonist of the human C-C motif chemokine receptor 4 (CCR4) that inhibits the migration and downstream activation of T-helper Type 2 (Th2)...
2.
Jackson J, Shibuya G, Ravishankar B, Adusumilli L, Bradford D, Brockstedt D, et al.
J Med Chem
. 2022 Sep;
65(19):12895-12924.
PMID: 36127295
General control nonderepressible 2 (GCN2) protein kinase is a cellular stress sensor within the tumor microenvironment (TME), whose signaling cascade has been proposed to contribute to immune escape in tumors....
3.
Jorapur A, Marshall L, Jacobson S, Xu M, Marubayashi S, Zibinsky M, et al.
PLoS Pathog
. 2022 Jan;
18(1):e1010200.
PMID: 35025968
The Epstein-Barr Virus (EBV) is involved in the etiology of multiple hematologic and epithelial human cancers. EBV+ tumors employ multiple immune escape mechanisms, including the recruitment of immunosuppressive regulatory T...
4.
Marshall L, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, et al.
J Immunother Cancer
. 2020 Nov;
8(2).
PMID: 33243932
Background: Checkpoint inhibitors (CPIs) such as anti-PD(L)-1 and anti-CTLA-4 antibodies have resulted in unprecedented rates of antitumor responses and extension of survival of patients with a variety of cancers. But...
5.
Ohol Y, Sun M, Cutler G, Leger P, Hu D, Biannic B, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):1970-1980.
PMID: 32788207
The deubiquitinase USP7 regulates the levels of multiple proteins with roles in cancer progression and immune response. Thus, USP7 inhibition may decrease oncogene function, increase tumor suppressor function, and sensitize...
6.
Robles O, Jackson J, Marshall L, Talay O, Chian D, Cutler G, et al.
J Med Chem
. 2020 Jul;
63(15):8584-8607.
PMID: 32667798
The C-C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (T) as well as other circulating and tissue-resident T cells. T can be recruited to the tumor...
7.
Leger P, Hu D, Biannic B, Bui M, Han X, Karbarz E, et al.
J Med Chem
. 2020 Apr;
63(10):5398-5420.
PMID: 32302140
USP7 is a promising target for cancer therapy as its inhibition is expected to decrease function of oncogenes, increase tumor suppressor function, and enhance immune function. Using a structure-based drug...
8.
Jackson J, Ketcham J, Younai A, Abraham B, Biannic B, Beck H, et al.
J Med Chem
. 2019 Jul;
62(13):6190-6213.
PMID: 31259550
Recruitment of suppressive CD4 FOXP3 regulatory T cells (T) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents....
9.
Hale C, Cheng Q, Ortuno D, Huang M, Nojima D, Kassner P, et al.
Autophagy
. 2016 Apr;
12(4):713-26.
PMID: 27050463
Autophagy is the primary process for recycling cellular constituents through lysosomal degradation. In addition to nonselective autophagic engulfment of cytoplasm, autophagosomes can recognize specific cargo by interacting with ubiquitin-binding autophagy...
10.
Finkbeiner S, Frumkin M, Kassner P
Neuron
. 2015 Apr;
86(1):160-74.
PMID: 25856492
Unbiased discovery approaches have the potential to uncover neurobiological insights into CNS disease and lead to the development of therapies. Here, we review lessons learned from imaging-based screening approaches and...